Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.
All News
Advertisement
The research centers on CD8+ T cells, which can recognize and attack the influenza virus.
Advertisement
The new formulation will provide patients with a faster alternative for management of suspected myocardial infarction.
Indivior’s once-monthly schizophrenia treatment risperidone (Perseris) extended-release injectable suspension has launched in the United States.
Advertisement
Advertisement
According to the CDC, major interventions are in need among at-risk populations in order to reach a goal of 90% decrease of HIV infections in 10 years.
The CDC has declared immunizations one of the greatest health achievements of the 20th century, but vaccination rates among adults remain suboptimal.
Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.
Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5